Avacta Group (LSE:AVCT) has had a busy autumn. The cancer drug developer raised about £12.5m in early October 2026, presented clinical and preclinical data from its pre|CISION platform at major conferences, and said on 4 November that it would present a new dual-payload drug candidate. The flow of news comes as the company works to extend its cash runway ahead of first efficacy data from its lead programme in 2027.

What the company does

Avacta is a clinical-stage biotechnology company developing tumour-targeted cancer therapies based on its pre|CISION technology. The approach is designed to keep a chemotherapy payload inactive until it reaches the tumour, where an enzyme called FAP releases it, with the aim of reducing toxicity to healthy tissue. Its lead clinical asset is AVA6103, an exatecan-based drug in the FOCUS-01 trial. AVA6000, also known as faridoxorubicin, is in Phase 1b, and AVA6207 is a next-generation dual-payload candidate. The company has been divesting its diagnostics division, which is now reported as discontinued.

Latest developments

On 5 October 2026 Avacta proposed a placing and subscription to raise about £12.5m at 68p per share, a 5.6% discount to the closing price on 29 September, and announced the result the following day. It said the proceeds would extend the cash runway into the second quarter of 2027, advance AVA6103, AVA6000 and AVA6207, and repay £2.5m of a Convertible Bond instalment due on 20 October.

Subsequent announcements covered presentations on AVA6000 and AVA6103 at ESMO 2026, a release on 26 October headed by the claim that progression-free survival nearly doubled with faridoxorubicin treatment, preclinical data for AVA6103 in Enhertu-resistant gastric tumour models, and participation in the Jefferies Global Healthcare Conference.

Financial picture

Interim results for the six months to 30 June 2026, published on 30 September, showed cash and short-term deposits of £20.27m at 30 June, falling to £10.59m by 31 August. The operating loss was £13.91m, against £14.18m a year earlier, while research costs rose to £9.69m from £7.20m as R&D spending increased. The loss from continuing operations after tax was £19.02m.

The going-concern note stated that a material uncertainty exists and that the company depends on raising further funds. Convertible bond principal of £19.2m was outstanding at 30 June, with accelerated payments settled in cash in July and September. Avacta does not pay a dividend.

Sector and index context

Avacta is one of the more prominent biotechnology names on the FTSE AIM All Share Index. Like many AIM drug developers, it relies on repeated Equity raises, and its share price tends to react sharply to clinical readouts, partnering news and financing terms. Interest in targeted cancer payloads, including antibody-drug conjugates such as Enhertu, gives context to its peptide-drug conjugate approach.

Key risks

Funding is the central risk: the stated runway only reaches the second quarter of 2027, and further raises could dilute shareholders. Convertible bond repayments add pressure on cash. Clinical risk is high, as early-stage data may not be repeated in larger trials, and the company's plan to advance AVA6000 through a Partnership depends on reaching an acceptable deal.

What to watch next

Key catalysts include the dual-payload candidate presentation, any partnering agreement for AVA6000, and first efficacy data from the FOCUS-01 trial of AVA6103, which the company expects in the first half of 2027. Progress on the diagnostics divestment and any further financing will also be closely followed.